Heather Greene, NP

home / authors / heather-greene-np

Articles

Toxicities Associated With VEGF TKIs and Checkpoint Inhibitors in mRCC

Toxicities Associated With VEGF TKIs and Checkpoint Inhibitors in mRCC

Heather Greene, NP
March 15th 2019

Heather Greene, a nurse practitioner at West Cancer Center, discusses the toxicities that are associated with VEGF TKIs and checkpoint inhibitors in metastatic renal cell carcinoma (mRCC).

Read More

Common Treatment-Related Toxicities in mRCC

Common Treatment-Related Toxicities in mRCC

Heather Greene, NP
December 11th 2018

Heather Greene, a nurse practitioner at West Cancer Center, discusses common treatment-related toxicities in metastatic renal cell carcinoma (RCC).

Read More

Heather Greene on Immune-Related Adverse Events in Patients With NSCLC

Heather Greene on Immune-Related Adverse Events in Patients With NSCLC

Heather Greene, NP
March 21st 2018

Heather Greene, a nurse practitioner at West Cancer Center, discusses the most common immune-related adverse events (AEs) in patients with non–small cell lung cancer (NSCLC), and whether or not these AEs vary between agents.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data